Joyce Pagan

Most Recent Articles by Joyce Pagan

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

Prior Bortezomib Lowers Incidence of Lenalidomide-Induced Skin Toxicity in Multiple Myeloma

By

A study presented at ESMO 2018 demonstrated that incidence of skin toxicity in patients with multiple myeloma undergoing lenalidomide therapy was lower in those who received prior bortezomib.

Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype

Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype

By

In a review of data from DANHES study, researchers determined the hazard ratio for developing myeloproliferative neoplasm — any or by subtype — among smokers, occasional smokers, and ex-smokers, compared with never smokers.

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma

By

A retrospective follow-up study demonstrates that tandem autologous-allogeneic is safe for standard and high-risk multiple myeloma. However, benefits do not extend to patients with ultra-high-risk disease and those with disease progression after autologous HCT.

Culturally Sensitive Navigation Bridges Some Care Gaps for Latino Adults With Advanced Cancer

Culturally Sensitive Navigation Bridges Some Care Gaps for Latino Adults With Advanced Cancer

By

Researchers explored the effectiveness of tailoring patient navigation programs to address cultural and language barriers for Latino adults with advanced cancer.

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

By

Researchers sought to determine if nedaplatin could effectively manage malignancy-induced MPE in patients with cancer with less toxicity than cisplatin.

More Articles by Joyce Pagan

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs